The manufacturer announced that the World Health Organization (WHO) granted pre-qualification (PQ) status to Biological E's innovative oral polio vaccine type 2 (nOPV2).

A next-generation oral vaccination called nOPV2 was created to stop outbreaks of vaccine-derived Poliovirus type 2 (cVDPV2). The Bill & Melinda Gates Foundation has awarded Biological E, a Hyderabad-based pharmaceutical and vaccine company, a grant to help fulfill the rising demand worldwide.

The WHO pre-qualification, according to Mahima Datla, managing director of Biological E, was a noteworthy achievement. This vaccine was created especially to allay worries regarding vaccine-associated paralytic polio (VAPP). According to her, the typical OPV is caused by the vaccine virus reverting to a virulent form, and it has happened in about 2 to 4 cases per million births.

Biological E has partnered with PT Bio Farma (PTB), an Indonesian company that was the first to obtain WHO pre-qualification as a manufacturer of the nOPV2 vaccine. The business uses PTB and approved large-scale production facilities to supply the technologies needed to produce over 500 million doses of the nOPV2 vaccine annually. This next-generation live, attenuated oral vaccine is intended for immunization in areas plagued by cVDPV2 outbreaks, a critical step in the fight against polio. It dramatically lowers the danger of circulating cVDPV2 outbreaks.

The vaccine can dramatically reduce the prevalence of cVDPV2 outbreaks, protecting communities from the devastating effects of polio, as demonstrated by its practical use in outbreak zones. In outbreak areas, more than a billion doses of nOPV2 would be required. The regulatory bodies in India have given BE permission to produce the vaccine for export.